From: Interleukin-6 inhibition in the management of non-infectious uveitis and beyond
Target | Structure | Dose and route of administration | Current indications (FDA approved) | Potential indications | |
---|---|---|---|---|---|
Tocilizumab | sIL-6R mIL-6R | Recombinant humanized | 4–8 mg/kg IV q4wk 162 mg SC q2wk/q4wk | RA, JIA, GCA | Takayasu’s arteritis, Behçet’s disease, adult onset Still’s disease, multicentric Castleman’s disease (approved in Japan), relapsing polychondritis, Cogan’s disease, inflammatory myositis, lupus, NIU |
Sarilumab | sIL-6R mIL-6R | Human mAb | 200 mg SC q2wk | RA | RA, NIU |
Sirukumab | IL-6 | Human mAb | FDA approval denied for RA | n/a | – |
Siltuximab | IL-6 | Chimeric | 12 mg/kg q3wk | Castleman’s disease | Multiple myeloma, currently no studies in NIU |
Clazakizumab | IL-6 | Humanized mAb | 25–200 mg SC q4wk | Not FDA approved | Renal transplant, psoriatic arthritis, RA |
Olokizumab | IL-6 | Humanized mAb | 64 mg SC q2wk/q4wk | Not FDA approved | RA |
ALX-0061 | sIL-6R mIL-6R | Nanobody (heavy chain-only) | n/a | Not FDA approved | SLE, RA |
MEDI 5117 | IL-6 | Human mAb | n/a | Not FDA approved | – |